Geistlich hands over catheter device to Théradial
Schlieren/Wolhusen/Nantes - Geistlich has sold its TauroSept device to Théradial. The antimicrobial medical product for the prevention and treatment of catheter infections will in future be distributed by the French company Théradial.
Geistlich Pharma has decided to divest its product TauroSept. Commercialization responsibilities have been transferred to Théradial, a company based in the French city of Nantes. This is an antimicrobial medical device that has been used for decades for parenteral nutrition, oncology and dialysis for the prevention and treatment of catheter infections. Until now, TauroSept was manufactured by Geistlich Pharma AG from Wolhusen in the canton of Lucerne which forms part of the Geistlich Group based in Schlieren in the canton of Zurich.
According to a company press release, this step comes on the back of Geistlich’s decision to focus exclusively in future on its world-leading developments in the area of regenerative medicine. Théradial specializes in the distribution of medical products, in addition to pharmaceutical specialties for dialysis, gastroenterology, oncology and clinical nutrition. «In Théradial we have found a proven expert», comments David Wemans, Vice President of Regenerative Technologies at Geistlich. «TauroSept is thus in very good hands and will be able to continue building on its achievements as a leading antimicrobial medical device».
With TauroSept, Théradial has received an «extremely attractive product», as Geistlich states. It has been certified in line with MDR and is available in a new packaging concept, namely an ampoule.
